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ABSTRACT
Aspartate transcarbamoylase (ATCase) and Dihydroorotase (DHOase) catalyze the
second and third steps, respectively, in de novo pyrimidine biosynthesis. Both enzymes form an
active complex (DAC) in Aquifex aeolicus, where loop A of DHOase interacts with a domain of
ATCase. The main objective of this work is to determine the function of specific residues of loop
A in DAC interactions and to alter the catalytic activities through disruption of the interface
between the two enzymes from A. aeolicus. The ATCase and DHOase domains have been
expressed in Escherichia coli and purified using affinity chromatography. The interface of the
published three-dimensional structure of the non-covalently associated dodecamer of DHOase
and ATCase from A. aeolicus was examined using bioinformatics, and a peptide was designed to
block a specific hydrophobic region. In this work, several peptides have been synthesized by
solid phase peptide synthesis (SPPS). Assays were conducted to determine the binding affinities
of the peptides to the DHO-ATC complex.
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CHAPTER 1: INTRODUCTION

Introduction
Cancer is a disorder which involves uncontrolled cell division, resulting in a
destruction of body tissue. In the United States, cancer is the second highest cause for
deaths, with nearly one in every four people falling victim to it. Based on the data
provided by the American Cancer Society in its 2014 cancer incidence statistics, more
than 1,500,000 new cancer cases and more than 500,000 cancer deaths were estimated.
How does cancer form? Each cell in the body has DNA that carries the cell’s
information. If the DNA becomes damaged, the cell will not function normally. Cancer
starts when these abnormal cells start dividing uncontrollably,1 and there are many
mechanisms that these cancer cells employ to divide without any regulatory control.
Pyrimidine nucleotides have a major role in cell growth.2,3 In cancer, de novo
pyrimidine biosynthesis is upregulated. Thus, there is need for effective
chemotherapeutic agents that act by targeting the enzymes that catalyze this pathway in
the earliest steps.4 Understanding the role of the pyrimidine pathway in the rapid growth
of tumors can be achieved, in part, by understanding the process of pyrimidine de novo
biosynthesis in prokaryotic cells. The analogous pyrimidine biosynthetic enzymes from
the A. aeolicus bacteria are used as a model system because of their known homology
with the mammalian counterparts. Targeting the enzymes involved in the second and
third steps of this pathway in A. aeolicus may lead to the development of new drugs for
cancer in the long run.
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Pyrimidine Pathway
The pyrimidine pathway performs a major role in cell metabolism by activating
the precursors of DNA and RNA, CDP-triacylglycerol, and phosphoglyceride, which are
needed for assembling cell membranes, and the precursors needed for the glycosylation
of proteins and the synthesis of glycogen by UDP-Glucose. Moreover, the uridine
nucleotide, which is formed by pyrimidine biosynthesis,2 regulates a different
physiological process through extracellular receptors.3 Pyrimidine synthesis has two
different paths: the nucleotides can be reused by the salvage pathway, or they can be
synthesized de novo from small metabolites.2,3 The activation of these paths to
pyrimidine synthesis depends on the cell type, its growth phase, and its developmental
stage. In fully differentiated cells or in the resting stage, the rate of the de novo synthesis
is low because the required pyrimidine level is met by the salvage pathway. In contrast,
the rate of the de novo pyrimidine synthesis is high in proliferating cells in order to meet
the increased demand for the precursors of DNA and RNA, along with other
components.5 Therefore, better understanding of the de novo activity of pyrimidine
biosynthesis is necessary to elucidate the regulation of the growth-state-dependent
control mechanisms of this pathway and their breakdown and failure in cancer.
De novo Pyrimidine Biosynthesis
The pyrimidine de novo biosynthetic pathway effectively serves the rapid growth
of tumors.2 It is carried out by six enzymatic steps to form Uridine 5'-monophosphate
(UMP). The first three steps in pyrimidine de novo biosynthesis in mammalian cells are
catalyzed by three enzymes, Carbamoyl-phosphate synthetase II (CPSase II), Aspartate
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transcarbamoylase (ATCase), and Dihydroorotase (DHOase), referred to as CAD. These
enzymatic activities are all carried on a single polypeptide chain that forms carbamoyl
phosphate, carbamoyl aspartate, and dihydroorotate, respectively. These steps are
chemotherapeutic targets, since they catalyze the first steps of the pathway. The rest of
the pyrimidine pathway is catalyzed by dihydroorotate dehydrogenase (DHOdhase),
UMP Synthase (UMPSase), and CTP synthase (CTPSase) to form orotate, UMP, and
CTP, respectively (Figure 1).6,7 CAD is the key regulatory enzyme in mammalian de
novo pyrimidine biosynthesis because it catalyzes the first rate limiting step of the
pathway.

Figure 1: The de novo pyrimidine biosynthetic pathway.3
Aquifex aeolicus
A. aeolicus belongs to the Aquificales order, and is gram-negative with no capability
to form spores. Aquificales are hyperthermophilic bacteria that live in hot springs, both
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terrestrial and marine. Aquificales are autotrophs as they can use inorganic substances to
form nutritional organic substances.8 A. aeolicus is an extreme hyperthermophilic organism
with an ancient lineage. This bacteria grows in temperatures reaching up to 95°C, in a CO2,
O2, and H2 atmosphere.9 This property gives the enzymes from A. aeolicus great stability in
the face of changes in temperature, pressure, and levels of O2. This stability is an attractive
feature for research studies involving enzyme activity.

Figure 2: Comparison of the structural organization of the enzymes catalyzing the first
three steps of the de novo pyrimidine biosynthesis in mammals, A. aeolicus, and E.
coli.11
CAD Complex vs. Aquifex aeolicus Enzymes
The first three steps in de novo pyrimidine biosynthesis in mammals are
catalyzed by CAD.2,3 In prokaryotic cells, the enzymes involved in the pathway are
encoded by separate genes and have separate expressions. These enzymes can function
independently, such as in E.coli, or can be associated with a multifunctional complex as
in the case of A. aeolicus (Figure 2).10 The latter is similar in function to the mammalian
complex. Unlike the mammalian enzymes, the first three enzymes in the de novo
pyrimidine biosynthesis in A. aeolicus are monofunctional proteins. Furthermore, unlike
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the mammalian system, the first step catalyzed by the bacterial CPSase is not the
committed step as it catalyzes the formation of carbamoyl phosphate for both pyrimidine
and arginine biosynthesis.12 Therefore, the function of the second enzyme ATCase is
likely to be the first committed step in pyrimidine biosynthesis in A. aeolicus to catalyze
the formation of carbamoyl aspartate.3,12 The third enzyme DHOase catalyzes the
reversible step to form dihydroorotate from carbamoyl aspartate. This activity is
typically 10 fold lower than that of ATCase.

Figure 3: The second and third steps in pyrimidine biosynthesis. (A) ATCase catalyzes
the condensation of carbamoyl phosphate and aspartate to form carbamoyl aspartate and
phosphate. (B) DHOase catalyzes the formation of dihydroorotate and water from
carbamoyl aspartate and H+.11,13
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Figure 4: ATCase structure. (A) The residues at the interface between the carbamoyl
phosphate and aspartate domains (Lys 26 and Lys 138, yellow, space filled) are shown.
(B) A major residue for the two substrate binding (Lys 75, blue, space filled) is shown.
(C) The active site residues (Gln 219, Val 190, Phe 191, Leu 8, Gly 122, and Phe 103,
blue, space filled) are shown. This figure was prepared using PyMol viewer (PDB Id:
3B6N).13
Aspartate Transcarbamoylase in Aquifex aeolicus
ATCase catalyzes the formation of carbamoyl aspartate in the second step of
pyrimidine biosynthesis (Figure 3.A). ATCase in bacteria is classified into three groups
based on the number of subunits and the molecular mass. Class A is defined by the
association of two trimers and six DHOase monomers to form 480-kDa dodecamers,
e.g., Pseudomonas aeruginosa ATCase. In class B, there is association of two trimers
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and three regulatory dimers to form 310-kDa dodecamers, e.g., E. coli ATCase. Class C
is usually characterized by 100-kDa trimers, e.g., Bacillus subtilis.13 Interestingly,
ATCase in A. aeolicus differs from these classifications. A. aeolicus ATCase, a 34-kDa
subunit, is encoded by the gene pyrB. ATCase has two domains, namely, carbamoyl
phosphate and aspartate, connected internally through Lys 26 and Lys 138 (Figure 4).
ATCase in A. aeolicus is inactive as a monomer, and only functions when it forms a
trimer.13

Figure 5: The structure of A. aeolicus DHOase. It is an inactive monomer presumably
due to the intrinsically disordered loop (Loop A, green) blocking any access to the
active site. DHOase has a single zinc ion (yellow). This figure has been prepared using
the PyMol viewer (PDB Id: 1XRF).
Dihydroorotase Structure in Aquifex aeolicus
The first crystal structure of A. aeolicus DHOase allows its classification as a
type I dihydroorotase.14 This classification is based on the number of zinc ions and their
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function in DHOase, which is same as the DHOase domain in the mammalian CAD.3,14
The sequence homology between the DHOase domain of the mammalian CAD and A.
aeolicus DHOase is about 26% .11,14 This homology is higher, between the DHOase in
Aquifex aeolicus and mammalian CAD, than that found when compared to other
bacteria. For example, E. coli 15 DHOase has13% sequence homology with the DHOase
domain of CAD.11,14 These similarities demonstrate that Aquifex aeolicus can be used as
a model system to study the enzymes involved in de novo pyrimidine biosynthesis.

Figure 6: One ATCase monomer complexed with one DHOase monomer of the
dodecameric DHO-ATC complex (DAC).
DHO – ATC Complex
The first crystal structure of the dodecameric complex of dihydroorotase and
aspartate transcarbamoylase from A. aeolicus was solved in 2009.10 This structure is
predicted to be a possible model of mammalian CAD since it is the first structure of a
multienzyme complex in the pyrimidine pathway.10,11,14 Also, the active site of DHOase

9
in A. aeolicus has only one zinc atom, Znα. This zinc atom shows a square-pyramidal
geometry with four amino acid residues: His-61, His-63, Asp-153, Asp-305, and one
water molecule, all as ligands.11,14 Moreover, the metal binding signature sequence is
exactly the same as in CAD and differs by only one residue in E. coli. Although there is
a second zinc site, the absence of the second zinc ion does not seem to affect the
reversible reaction of carbamoyl aspartate to form dihydroorotate (Figure 3.B). Thus,
DHOase is activated by a mononuclear metal ion.15,16 Nevertheless, the DHOase in A.
aeolicus is inactive and only becomes active on association with ATCase, despite the
binding of the zinc.11,14 There are three factors which may explain why the isolated
enzyme DHOase in A. aeolicus, is inactive (Figure 5). First, there is no access to the
active site because of the bond between the Znα and Cys181. This blocking interaction is
not found in the DHOase in E.coli. Second, it may be because of the absence of the
second zinc atom in DHOase in A. aeolicus, although recent studies suggest that it is not
essential for catalytic activity.16 Third, there are three loops that have intrinsic disorders
around the active site that are likely blocking any access to it.10 The importance of these
three factors is highlighted in the structure of the stoichiometric complex of DHOase
associating with ATCase in A. aeolicus.10 The complex is a hetero dodecamer that forms
an unfilled space or cavity on the inside. The ATCase – DHOase complex (DAC) is
formed by two trimers of ATCase and three dimers of DHOase enzymes, 12 enzymes in
total, where all the active sites are facing the internal, aqueous phase. This specific
organization appears to facilitate the interaction between the active sites and activates the
DHOase in order to catalyze the third step in the de novo pyrimidine biosynthetic
pathway that results in the formation of dihydroorotate.10 Upon complex formation,
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Loop A of DHOase interacts with the ATCase domain rendering the DHOase active site
accessible (Figure 6).17
Importance of Loop A
Recently, enzyme assays were conducted to determine the binding affinities of
synthetic peptides from certain regions of loop A to DAC in A. aeolicus.17 The peptides
were used in different concentrations to determine the stoichiometry of the peptideprotein complex. The results indicated that the peptide, NEGEVSALLGLS, inhibited the
functional interaction of DAC in an allosteric manner. This peptide, which is part of
loop A, was shown to alter the catalytic activities of the DAC complex likely through the
disruption of the interface between the DHOase and ATCase domains.17 These results
provided a promising lead on the potential of loop A as a noncompetitive drug target to
control the second and third steps in de novo pyrimidine biosynthesis. The peptide,
DHCEDDKLA, may serve as a competitive inhibitor because it may bind directly to the
active site on the DHOase domain. However, the competitive inhibitor function of this
region of loop A has not been tested prior to this study.

11
Hypothesis
In loop A, residues 179 – 186 are involved in competitively inhibiting the DHOase
active site while residues 192 – 203 noncompetitively inhibit the ATCase active site.

179 DHCEDDKLAYGVINEGEVSALLGLSSRAPEAE 210

Goals
1. To determine the function of specific residues of loop A in DAC functional
interactions.
2. To alter the catalytic activities through disruption of the interface between the two
enzymes from A. aeolicus.
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CHAPTER 2: EXPERIMENTAL METHODS
Peptide Synthesis
The SPPS method was used to synthesize the peptide. 0.4 mmol amino acid,
protected by N-α-fluorenylmethyloxycarbonyl (Fmoc), and 0.4 mmol activating agent
hydroxylbenzotriazolyltetramethyluronium hexafluorophosphate (HBTU) (4X excess)
were added into a vial. 0.1 mmol of p-methylbenzhydrylamine (MBHA) resin was used
as the solid support to give a carboxamide terminus. The PS3 synthesizer was
programmed to couple amino acids, remove each Fmoc group, and wash with N,Ndimethylformamide (DMF) at each step. In order to cleave the peptide from the resin,
the peptide was treated by adding 0.5 mL distilled water, 0.5 mL phenol scavenger, and
10 mL trifluororacetic acid (TFA). The peptide resin was stirred for two hours at room
temperature. The peptide-containing solution was then removed from the resin through
filtration, following which cold diethyl ether was added for peptide precipitation. The
precipitant, the solid peptide, was collected by filtration and then dissolved in 35%
ACN/H2O and lyophilized. The peptides were dissolved in methanol first, and then the
resultant solution was purified by reverse-phase high performance liquid
chromatography (RP-HPLC) using an absorbance wavelength of 214 nm for detection.
The peptide solution was injected and run with linear gradient of 10 – 50% ACN in H2O
over two hours. The solution was collected in test tubes where peaks were observed. The
tubes containing pure peptide were combined and lyophilized before the purity was
confirmed by RP-HPLC. Electrospray ionization mass spectrometry (ESI-MS) was used
to confirm the molecular weight of the peptides. The resultant peptides were dissolved in
100% dimethyl sulfoxide (DMSO) with a final concentration of 2 mg/mL.
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Protein Expression
The pyrB and pyrC genes encoding A. aeolicus ATCase and DHOase were
cloned into an expression vector, pRSET, to purify the expressed protein with His-tag on
a Nickel resin. 3 μL of the plasmids pAApyrB and pAApyrC were transformed in a vial
with 40 μL of the competent cells (the E. coli strain BL21 (DE3*)) along with 5 μL of
helper plasmid pSJS1240. The mixture was incubated in ice for 30 min. The E. coli were
heat shocked for exactly 30 seconds in a 42°C water bath. 250 μL of pre-warmed SOC
medium was added to the E. coli cells. The vials were placed in a shaker at 37°C, 220
rpm, for one hour. The transformed cells were placed on a pre-prepared LB agar plate
containing 100 μg/mL ampicillin and 50 μg/mL spectinomycin, and grown at 37°C
overnight. After growing the cells overnight, the cells were centrifuged at 13,000 rpm at
4°C for 30 min. The medium was discarded and the pellets were re-suspended in 3 mL of
50 mM Tris/Cl buffer. Sonication was applied to disrupt the cells 6 times for 30 seconds.
The extracted cells were centrifuged at 13,000 rpm at 4°C for 30 min.
The recombinant protein was purified by Ni2+ affinity chromatography as the
proteins were expressed with a His tag. The supernatant was applied to a 1 mL Ni2+ProBond column equilibrated with 50 mM Tris-HCl and 200 mM NaCl (TN buffer). The
proteins were eluted with successive 1 mL aliquots of increasing concentrations of
imidazole from 50 to 400 mM in TN buffer and the fractions were collected. Analysis of
the fractions was accomplished by Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) with 10% acrylamide. Fractions containing pure A.
aeolicus ATCase and DHOase were applied to the bicinchoninic acid (BCA) assay kit to
determine protein concentration.
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Enzyme Assays
For the ATCase assay, the enzyme activity was measured by a colorimetric
method where the assay was performed as a function of enzyme concentration. The
samples were prepared by adding 500 μL of assay buffer (3 ml of 0.5 M Tris, 0.25 mL
aspartate, and H2O up to15 mL), enzyme (two assays, ATCase only and ATCase in
DAC, ATC-DHO, 2:3 ratio), and H2O up to 1 mL in culture tubes. The sample reactions
were initiated by adding the substrate (100 μL of 50 mM carbamoyl phosphate), mixed
and placed in a 70°C water bath. The total assay time was 3 min. After 3 min, 1 mL of
5% acetic acid was added to quench the reaction, followed by mixing and placement at
room temperature. 2 mL of color mix (antipyrine and monooxime, 1:2 ratio) was added
to each tube, which acted as an indicator for the product carbamoyl aspartate.
Absorbance at 466 nm of carbamoyl aspartate was measured after 60 min incubation at
60°C. Another ATCase assay was performed as a function of peptide concentration. The
peptides DHCEDDKLA and NEGEVSALLGLS were added at different concentrations.
For DHOase, the assay was performed as a function of enzyme concentration.
The samples were prepared by adding 500 μL of assay buffer (0.1 M Tris), enzymes
(DAC, ATC-DHO, 2:3 ratio), and H2O up to 1 ml in culture tubes. The sample reactions
were initiated by adding the substrate (50 μL of 80 mM dihydroorotate), mixed and
placed in a 70°C water bath. The assay proceeded as has been described in the ATCase
assay section.
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In all assays, the concentration of carbamoyl aspartate was calculated from
standard curves created with known concentrations of 10 mM carbamoyl aspartate. The
data plot is linear.
PyMol Viewer
Enzyme structures were visualized and modeled by the PyMol viewer software.
First, the structure was downloaded from a protein data bank website as a PDB File
(Text). From the PyMol molecular graphics system window, the sequence was displayed
in order to select the desired residues. The sequence appeared on the top of the PyMol
viewer window. Different commands (Action, Show, Hide, Label, and Color) from the
PyMol Names Panel were used to make the desired changes to the structure. The desired
residues within specific distances were selected. On the structure (the selected residues
are marked), the “actions” option appeared on a right-click of the mouse. The following
options were used: “around” and “residues within 4, 5, and 6 Å”
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CHAPTER 3: RESULTS AND DISCUSSION
Loop A, part of DHOase, has been reported as a significant loop by which
DHOase and ATCase activities are functionally coupled, and loop A appeared to be
wedged between the two ATCase domains. The residues of loop A are believed to have
separate effects based on the location of these residues. It is critical to identify the
specific function of these residues in order to potentially regulate the enzyme activity
with greater control. Moreover, the specific function can be identified by determining
where and how specific parts of loop A bind to specific regions between these two
enzymes (Figure 7).

Figure 7: Loop A of DHOase. The sequence of loop A (top) in different colors
corresponds to those in the structure (bottom).
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The peptides HCE, DHCEDD, DHCEDDKLA, and NEGEVSALLGLS were
prepared using the PS3 synthesizer with high purity of 99 to 100% after purification.
The purification of the peptides was confirmed by RP-HPLC. The peptide yield on SPPS
is generally around 20 to 50%, and different yield percentages were obtained
experimentally (Table 1). The peptides were identified by ESI-MS and dissolved in
DMSO with a final concentration of 2 mg/mL.
Table 1: Synthetic peptide yields

Peptide

Percent yield

HCE

31 %

DHCEDD

33 %

DHCEDDKLA

48 %

NEGEVSALLGLS

25 %

The A. aeolicus ATCase protein was expressed in E. coli BL21 (DE3*) and
purified using Ni2+ affinity chromatography. Subsequent to extensive washing, about
2/3 of the ATCase protein was eluted with 200 mM imidazole/TN buffer and a third was
eluted with 300 mM imidazole/TN buffer. The molecular mass of the purified ATCase
corresponded to 34-kDa as compared to the protein ladder, a reference to determine the
mass of the unknown protein (Figure 8).
The DHOase protein from A. aeolicus was expressed in E. coli BL21 (DE3*).
The purification was accomplished by Ni2+ affinity chromatography. About 75% of the
protein was eluted with 200 mM imidazole/TN buffer and the rest of the total protein
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was eluted with 300 mM imidazole/TN buffer. As compared to the ladder, the
molecular mass corresponded to that reported in the literature, 46-kDa (Figure 9).

Figure 8: SDS-PAGE gel of A. aeolicus ATCase expression, purified by Ni2+ affinity
chromatography.

Figure 9: SDS-PAGE gel of A. aeolicus DHOase expression, purified by Ni2+ affinity
chromatography.
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The effect of the peptide NEGEVSALLGLS has been reported previously as an
allosteric noncompetitive inhibiter.18 The peptide acted by mimicking the end segment of
loop A in DHOase in order to diminish the interaction necessary with ATCase.
Interestingly, the activity of the isolated ATCase subunit was more affected by the
peptide NEGEVSALLGLS than the ATCase activity in DAC. The catalytic activity of
both the ATCase and DHOase were affected (Figures 10, 11). Percent inhibition of the
peptide was variable (Table 2), which helped raise several questions, such as: a) Which
one of these enzymes is most affected by the peptides? b) How does the DAC complex
modulate the effect of the peptides on the isolated enzymatic components? c) Which
part of loop A affects only the ATCase or DHOase activities?

Figure 10: The ATCase assay and the effect of the peptide as a function of increasing
enzyme concentration. The peptide used is NEGEVSALLGLS (orange) (A) The
ATCase activity of the isolated ATCase subunit (green). (B) The ATCase activity of
DAC (blue).
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The effect of the peptides reflecting different regions of loop A on the activity of
the isolated ATCase subunit was measured by measuring the ATCase activity. The
enzymatic assay was performed at a variety of enzymes concentrations. Different
peptides representing unique and/or overlapping regions of the first segment of loop A,
residues 179 – 186, were synthesized (HCE, DHCEDD, DHCEDDKLA). In the case of
all the peptides above, the effect on the isolated ATCase activity was not evident in the
region of lower protein concentrations. No effect was observed upon the addition of the
peptides (HCE, DHCEDD, DHCEDDKLA) to lower concentrations of the isolated
ATCase domain (2.5 μL of 0.164 μg/mL) suggesting a concentration-dependence
response to the peptides (Figure 12). Increasing the concentration of the protein,
however, showed the inhibitory effect of the peptides on the isolated ATCase activity
(Table 2).

Figure 11: The DHOase activity inhibition of DAC as a function of increasing enzyme
concentration. DHOase activity in the absence of peptide (black) and the presence of the
peptide NEGEVSALLGLS (orange).

21

Figure 12: The activity of the isolated ATCase subunit as a function of increasing
enzyme concentration. The isolated ATCase subunit activity (green) and the effect of
different peptides (orange). (A) HCE peptide. (B) DHCEDD peptide. (C)
DHCEDDKLA peptide.
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Figure 13: The ATCase activity of DAC inhibited by short peptides. The activity of
ATCase of DAC (blue) and the effect of different peptides (orange) as a function of
increasing enzyme concentration. (A) HCE peptide. (B) DHCEDD peptide. (C)
DHCEDDKLA peptide.
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Figure 14: The DHOase activity of DAC inhibited by short peptides. The activity of
DHOase of DAC (black) and the effect of different peptides (orange) as a function of
increasing enzyme concentration. (A) HCE peptide. (B) DHCEDD peptide. (C)
DHCEDDKLA peptide.
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Similar percent inhibitions were observed for the peptides’ effect on the activity
of ATCase in the DAC complex. The DAC complex was prepared by the addition of 2.5
μL of (0.164 μg/μl) ATCase and (0.238 μg/μl) DHOase (2:3 ratio) and the peptides (with
final concentration 0.2 mg/ml) were added (Figure 13). The percent inhibition of the
ATCase activity in the DAC complex were found to be in the same range as in those
observed with the isolated subunit.
The effects of the peptides, HCE, DHCEDD, DHCEDDKLA, on the activity of
DHOase of DAC was measured starting at the lowest concentration, 2.5 μL of (0.164
μg/μL) ATCase/ (0.238 μg/μL) DHOase (2:3 ratio), and with increasing enzyme
concentration (Figure 14). The effects are similar to those found on the ATCase activity
of DAC; however, the percent inhibition on DHOase of DAC activities varies between
these peptides, which reflects the effect of the specific residues on the DHOase activity
of DAC.
Table 2: Peptides effect (inhibition %) on the isolated ATCase subunit, ATCase of
DAC, and DHOase of DAC.

Peptide

ATCase activity
inhibition %
(ATCase)

ATCase activity
inhibition %
(DAC)

DHOase activity
inhibition %
(DAC)

HCE

43.7

25.8

35.1

DHCEDD

5.26

24.2

23.4

DHCEDDKLA

38.3

29.3

40.6

NEGEVSALLGLS

44.2

29.3

10.9
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Figure 15: Percent of ATCase activity as a function of increasing peptide concentration.
The effect of the peptides NEGEVSALLGLS (orange) and DHCEDDKLA (blue) was
determined (A) The ATCase activity of the isolated ATCase subunit. (B) The ATCase
activity of DAC.
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The effect on the ATCase activity of increasing peptide concentration (0.1, 0.3,
0.4, and 0.5 mg/mL) was different between the isolated ATCase subunit activity and the
ATCase activity of DAC. The peptide, DHCEDDKLA, affects the isolated ATCase
subunit activity more than the peptide, NEGEVSALLGLS. The ATC activity of DAC
with NEGEVSALLGLS, however, has more of a dependence upon the peptide
concentration as compared to the effect of the peptide, DHCEDDKLA, which does not
seem to have a significant effect on the ATCase activity of DAC (Figure 15).
All of the results are summarized in Tables 3 and 4.

Figure 16: The residues of the ATCase active site interacting with part of loop A,
NEGEVSALLGLS (white).
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Figure 17: Part of loop A interaction with the metal binding residues in the DHOase.
Table 3: Peptide effect on ATCase activity.

Peptide

ATCase
ATCase
inhibition inhibition
%
%
(alone)
(DAC)

Data Interpretation
•

HCE

43.7

25.8

•
•

DHCEDD

5.26

24.2

•
•

DHCEDDKLA

38.3

29.3

•
•
•

NEGEVSALLGLS

44.2

29.3
•

DHOase is protecting against the
inhibition of ATCase by HCE
It might be a concentration
dependence
DHCEDD is poor inhibitor of
ATCase alone but not in DAC
The effect could be due to inhibition
of DHOase
The extra residues KLA are important
in restoring the inhibition by HCE
The negative charge of D’s is not
inhibiting
Inhibits ATCase non-competitively
DHOase protects ATCase from the
inhibition
It might be a concentration
dependence
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Table 4: Peptide effect on DHOase activity.

Peptide

HCE

DHOase
inhibition
%
(DAC)
35.1

Data Interpretation
•

The peptide HCE inhibits DHOase

•

HCE is the minimum region needed to inhibit the
DHOase

•
DHCEDD

23.4

DHCEDDKLA

40.6

which explain the inhibition of ATCase in DAC
•

10.9

The positive region K increase the inhibition of
DHOase

•
NEGEVSALLGLS

It is possible that DHCEDD inhibits DHOase

The inhibition might be indirect, through ATCase
inhibition, with a small effect on DHOase
inhibition
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CHAPTER 4: CONCLUSIONS AND RECOMMENDATIONS
The DHOase appears to be protective against the inhibition of ATCase by HCE,
and it might be a concentration dependent effect. DHCEDD is a poor inhibitor of
ATCase alone, but not in DAC. The effect could be due to the inhibition of DHOase.
The extra residues, KLA, are important in restoring the inhibition by HCE. The negative
charge of the D residues is not inhibiting. Moreover, the peptide HCE inhibits DHOase.
HCE is the minimum region needed to inhibit the DHOase. It is possible that DHCEDD
inhibits DHOase, which explains the inhibition of ATCase in DAC. The positive region
provided by K increases the inhibition of DHOase. Additionally, the peptide
NEGEVSALLGLS inhibits ATCase non-competitively and DHOase protects ATCase
from this inhibition. The inhibition of DHOase activity of DAC by NEGEVSALLGLS
might be indirect, through ATCase inhibition, with small effects on DHOase inhibition
(Tables 3 and 4).
Further studies are needed to confirm these results. These may be achieved by
performing dihydroorotate saturation curves with and without peptides, specifically
HCE, to calculate and observe the effect on Km. Also, it is crucial to find the minimum
sequence of NEGEVSALLGLS that can serve as a non-competitive inhibitor with high
affinity. It is important to construct DHCEDDKLA with changes in HCE and mutate
HCE one residue at a time.
Proposed peptides for future work are suggested as follows: (a) residues that
interact with the ATCase active site (Figure 16); GEVSALLG at 4 Å, EGEVSALLGL at
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5 Å, and EGEVSALLGLS at 6 Å, (b) residues at the DHOase active site (Figure17);
D*CEDDKLA, DH*EDDKLA, and DHC*DDKLA (where * is a mutant residue).
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